Astellas Pharma (ALPMY) Stock Chart & Stock Price History $11.09 -0.13 (-1.15%) As of 10:16 AM Eastern Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock Astellas Pharma Stock Price Performance The Astellas Pharma (ALPMY) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 2.41%, with a year-to-date return of 14.76%. In the past month, the stock has increased 12.80%, reflecting recent market activity. As of the latest close, Astellas Pharma traded at $11.22 with a market cap of and volume of 142,255 shares. Five years ago, the stock traded at $16.36, representing a 32.24% decrease over that period. At the time, it had a market cap of and a volume of 672,912 shares. Receive ALPMY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.06%1 Month Performance+12.80%3 Month Performance+21.54%Year-To-Date Performance+14.76%1 Year Performance-2.41%5 Year Performance-32.24% ALPMY Stock Chart for Thursday, August, 14, 2025 ALPMY Chart by TradingView Astellas Pharma Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/13/2025$11.22$11.22-0.04%$11.32$11.18142,255 shs$0.0008/12/2025$10.96$11.22+2.39%$11.33$10.91141,858 shs$0.0008/11/2025$10.97$10.96-0.11%$11.31$10.5694,764 shs$0.0008/08/2025$10.85$10.97+1.11%$11.31$10.5364,760 shs$0.0008/07/2025$10.78$10.85+0.67%$10.89$10.81119,722 shs$0.0008/06/2025$10.68$10.78+0.91%$10.80$10.7240,747 shs$19.50 billion08/05/2025$10.61$10.68+0.66%$10.72$10.61113,734 shs$0.0008/04/2025$10.57$10.61+0.38%$10.80$10.38139,820 shs$0.0008/01/2025$10.34$10.57+2.22%$10.57$10.03268,036 shs$0.0007/31/2025$10.35$10.34-0.10%$10.90$10.34175,049 shs$18.71 billion Get the Latest News and Ratings for ALPMY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. 07/30/2025$10.07$10.35+2.78%$10.60$10.21136,910 shs$0.0007/29/2025$9.97$10.07+1.00%$10.15$9.99186,112 shs$0.0007/28/2025$9.96$9.97+0.10%$10.04$9.9168,447 shs$18.04 billion07/25/2025$10.06$9.96-0.99%$10.00$9.9351,632 shs$18.02 billion07/24/2025$10.14$10.06-0.81%$10.10$10.0659,006 shs$0.0007/23/2025$9.69$10.14+4.67%$10.15$9.80103,928 shs$0.0007/22/2025$9.79$9.69-1.02%$9.79$9.66193,825 shs$0.0007/21/2025$9.69$9.79+1.03%$9.80$9.48109,575 shs$0.0007/18/2025$9.73$9.69-0.41%$9.72$9.4683,023 shs$0.0007/17/2025$9.66$9.73+0.77%$9.73$9.59114,340 shs$0.0007/16/2025$9.66$9.66-0.04%$9.80$9.59652,149 shs$0.0007/15/2025$9.83$9.66-1.71%$9.80$9.62314,739 shs$17.48 billion07/14/2025$9.51$9.83+3.34%$10.15$9.641.14 million shs$0.00 Related Companies ACUS Stock Chart AOLS Stock Chart AOBI Stock Chart AXMP Stock Chart BIOAF Stock Chart BSPM Stock Chart CDXI Stock Chart COTQF Stock Chart HESG Stock Chart IAGX Stock Chart Receive ALPMY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:ALPMY) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access